Ipodix Multi-pass Transmembrane Protein Expression Services: Pioneering Solutions for Membrane Protein Research and Industrialization
I. Technological Breakthroughs: Tackling Four Core Challenges in Transmembrane Protein Development
To address the structural complexity of multi-pass transmembrane proteins (e.g., GPCRs, ion channels), Ipodix has developed the MEMPro™ platform, systematically resolving challenges in expression, purification, and stabilization, achieving an industry-leading project success rate of >75%.
1. High-Efficiency Expression Systems
● Host Optimization: Engineered mammalian cells (CHO/HEK293) with enhanced membrane structures, achieving transmembrane protein yields of 0.5–2 mg/L (5–8x higher than traditional methods).
● Targeted Liposome Encapsulation: Mimics native membrane environments to maintain correct folding of 7-transmembrane proteins, with >90% functional validation success.
2. Stable Conformation Preservation
● Proprietary molecular chaperone cocktails (12 auxiliary factors) to suppress protein aggregation.
● Disulfide bond accuracy >95%, α-helix content >85%.
3. Gentle Purification Processes
● Non-ionic detergent screening system (30+ detergent combinations).
● Affinity chromatography paired with SEC, achieving >60% target protein recovery.
4. Functional Activity Validation
● Integrated validation platforms: Patch-clamp, SPR, fluorescent calcium flux assays.
● Ligand-binding sensitivity at nM level.
II. Service Workflow: End-to-End Solutions from Gene to Functional Validation
Ipodix’s standardized development process reduces average timelines to 8–12 weeks:
Stage 1: Needs Analysis & Design (1–2 weeks)
• Free transmembrane domain bioinformatics analysis (topology prediction, hydrophobicity mapping).
• Custom expression system selection: mammalian/insect cell/liposome reconstitution.
Stage 2: Gene Construction & Optimization (2–3 weeks)
• Codon optimization for 10 expression hosts.
• Signal peptide library screening (membrane localization efficiency >85%).
Stage 3: Expression & Membrane Localization (3–4 weeks)
• Low-shear transfection technology (cell viability >90%).
• Fluorescent tagging validation (e.g., GFP fusion).
Stage 4: Purification & Refolding (2–3 weeks)
• Nanodisc assembly for transmembrane stability.
• Detergent exchange process (CMC precision control).
Stage 5: Functional Validation & Delivery (1–2 weeks)
• Basic Testing: SDS-PAGE, Western Blot, CD spectroscopy.
• Advanced Testing: Ligand binding, ion channel permeability.
III. Applications: Empowering Transmembrane Protein Research and Industrialization
Full-spectrum solutions across the R&D-to-commercialization value chain:
1. Drug Target Development
● GPCR drug R&D: Successfully expressed 5 GPCR classes (A, B, C families).
● Case: μ-opioid receptor development for analgesia achieved >80% ligand inhibition.
2. Antibody Drug Development
● Membrane protein antigen production in 4 weeks.
● Case: Anti-HER2 mAb for cancer therapy improved epitope recognition accuracy by 3x.
3. Structural Biology Research
● Cryo-EM sample prep: Purity >95%, particle uniformity >90%.
● Case: Resolved 3.2Å-resolution structure of voltage-gated sodium channel.
4. Diagnostic Reagent Development
● Batch-to-batch consistency (CV <5%).
● Case: Autoimmune disease test kit sensitivity improved to 0.1 IU/mL.
5. Industrial Enzyme Engineering
● Thermostable lipase development (70°C activity retention >80%).
● Case: Biofuel enzyme catalytic efficiency increased by 40%.
IV. Success Stories: Trusted by Global Clients
Academic Collaboration
• Challenge: Express astrocyte channel protein with 4 transmembrane domains.
• Solution: Liposome reconstitution system.
• Result: Active protein obtained; findings published in Cell sub-journal.
Pharmaceutical Partnership
• Challenge: GPBAR1 expression <0.1 mg/L for metabolic disease drug development.
• Solution: Targeted liposome encapsulation.
• Result: Yield increased to 1.2 mg/L, accelerating lead compound screening by 6 months.
IVD Company Case
• Requirement: Develop 7 viral transmembrane antigens for respiratory pathogen detection.
• Outcome: All antigens delivered within 4 months.
V. Quality Assurance: Full-Cycle Control & Client Commitment
Three-tier quality system ensures data reliability and reproducibility:
Material Control
● Cell banks validated via STR profiling and mycoplasma testing (quarterly rechecks).
● Key reagents certified to USP standards.
Process QC
● Milestone testing: Membrane localization efficiency, detergent screening reports.
● Electronic Lab Notebook (ELN) for traceable data management.
Delivery Standards
● Basic Grade: Purity >80% (SDS-PAGE) with topology validation.
● Research Grade: Purity >90%, includes CD spectra & activity data.
● Drug Development Grade: ICH-compliant with full CMC documentation.
Client Benefits
● NDA Compliance: Encrypted data storage.
● Technology Transfer: SOPs and on-site training.
● Post-Sales Support: 3 months of technical consultation.
Why Choose Ipodix?
● 300+ transmembrane protein projects completed.
● Serving research institutes and pharma across 10 countries.
● 30% faster delivery than industry average.
● Technical team with 12+ years of average experience.
Consult Now!
● Submit your protein sequence to receive a customized development plan within 72 hours.
➔ First-time clients receive free transmembrane domain analysis!
● Priority scheduling and dedicated project manager support.
